The symptoms shown by those infected with Coronavirus can vary widely. When searching the Internet, for symptom lists, you will find that often (but not always the Symptoms of a COVID-19 infection are similar to those found with respiratory illnesses including the flu and common cold. They include:
- Cough – usually a Dry Cough
- Sore throat
- Difficulty breathing
- Pneumonia in severe cases
Video is courtesy of the Science Insider YouTube channel.
Two unique symptoms which have recently been discovered, is the loss of Taste and Smell. One person described it to be like eating some Chocolate Ice cream and not being about to discern the Chocolate taste. The loss of one’s sense of smell can also point to a Coronavirus infection.
Stomach issues have also been mentioned by people who have suffered thru thru COVID-19 infection. One person mentioned pain in her stomach and wanting badly to burp but unable to do so.
Diarrhea has also been mentioned. Along with that is the idea of Fecal transmission of COVID-19. It is recommended to close the lid on a toilet before flushing. That would limit the spread of particles into the air in the washroom.
I might suggest that if at all possible, to limit the use of Public Washrooms. It is not just the idea of Fecal Transfer but an infected person would touch the Toilet’s Flush handle potentially leaving COVID-19 particles on the handle. If using a Public Washroom, please make sure to wash your hands using plenty of soap and hot water before leaving the Washroom. If possible dry your hands using paper towels. Why? It has been said the the hot air hand dryers may spread the COVID-19 virus particles into the air, which you then breathe.
There was also an informative article published by The Harvard Gazette. Click on the link to view that article:
“Study confirms vitamin D protects against colds and flu”
This info about Vitamin D may also help patients suffering for Coronavirus. See a prior post on this site for more info about Vitamin D and Coronavirus.
Vitamin C is not a patented drug and so is low cost. The use of Vitamin C as a treatment protocol for Coronavirus infections is rarely mentioned in the main news media. When one gets sick, Vitamin C in your body is depleted.
There were initial reports out of China that Coronavirus patients were being given intravenous Vitamin C. Vitamin C is also know to help patients who get Sepsis, which can also be the result of acquiring Coronavirus.
A new report has been published by Medicine in Drug Discovery, a peer reviewed journal by Elsevier, which details treating Coronavirus Patients using intravenous Vitamin C.
Click on the report title link below to visit the Elsevier’s Medicine in Drug Discovery site to read the report:
The report is as follows courtesy of Elsevier and Medicine in Drug Discovery:
Author links open overlay panel Richard Z.Cheng
The COVID-19 (SARS-2-Cov) pandemic, first reported in Wuhan, China, is now spreading to many continents and countries, causing a severe public health burden. Currently, there is no vaccine or specific antiviral drug for this deadly disease. A quick, deployable and accessible, effective and safe treatment is urgently needed to save lives and curtail the spreading. Acute respiratory distress syndrome (ARDS) is a key factor of fatality. Significantly increased oxidative stress due to rapid release of free radicals and cytokines is the hallmark of ARDS which leads to cellular injury, organ failure and death. Early use of large dose antioxidants, such as vitamin C (VC) may become an effective treatment for these patients. Clinical studies also show that high-dose oral VC provides certain protection against viral infection. Neither intravenous nor oral administration of high-dose VC is associated with significant side effects. Therefore, this regimen should be included in the treatment of COVID-19 and used as a preventative measure for susceptible populations such as healthcare workers with higher exposure risks.
Coronaviruses and influenza are among the pandemic viruses that can cause lethal lung injuries and death from ARDS [, , ]. Viral infections could evoke “cytokine storm” that leads to lung capillary endothelial cell activation, neutrophil infiltration and increased oxidative stress (reactive oxygen and nitrogen species). ARDS, characteristic of severe hypoxemia, is usually accompanied by uncontrolled inflammation, oxidative injury and damage to the alveolar-capillary barrier . Increased oxidative stress is a major insult in pulmonary injury including acute lung injury (ALI) and ARDS, two clinical manifestations of acute respiratory failure with substantially high morbidity and mortality [5,6].
In a report of 29 patients with COVID-19 pneumonia, 27 (93%) showed increased hsCRP, a marker of inflammation and oxidative stress . Transcription factor, nuclear factor erythroid 2 (nfe2)-related factor 2 (nrf2), is a major regulator of antioxidant response element (ARE)-driven cytoprotective protein expression. Activation of Nrf2 signaling plays an essential role in preventing cells and tissues from injury induced by oxidative stress. VC, an important component of the cellular antioxidant system , is beneficial to critical care management . Cytokine storm is observed in both viral and bacterial infections  and results in increased oxidative stress via a common and non-specific pathway. Since the prevention and management of oxidative stress could be realized by large dose of antioxidants, this approach may be applicable to COVID-19 with intravenous high-dose VC based on the outcome of three previous clinical studies involving a total of 146 patients with sepsis .
Hemila and colleagues reported that various high-dose intravenous VC infusions (e.g., 200 mg/kg body weight/day, divided into 4 doses) shortened the intensive care unit (ICU) stay by 97.8% , accompanied by a significant reduction in the mortality rate . Such an experience was reproduced among patients ill with severe influenza [13,14]. Indeed, dietary antioxidants (VC and sulforaphane) were shown to decrease oxidative stress induced acute inflammatory lung injury in patients receiving mechanical ventilation . In addition, oral VC (e.g., 6 g daily) was able to reduce viral infection risk  or to improve symptoms .
High-dose intravenous VC has also been successfully used in the treatment of 50 moderate to severe COVID-19 patients in China. The doses used varied between 2 g and 10 g per day, given over a period of 8–10 h. Additional VC bolus may be required among patients in critical conditions. The oxygenation index was improving in real time and all the patients eventually cured and were discharged . In fact, high-dose VC has been clinically used for several decades and a recent NIH expert panel document states clearly that this regimen (1.5 g/kg body weight) is safe and without major adverse events .
Because the development of efficacious vaccines and antiviral drugs takes time, VC and other antioxidants are among currently available agents to mitigate COVID-19 associated ARDS. Given the fact that high-dose VC is safe, healthcare professionals should take a close look at this opportunity. Obviously, well-designed clinical studies are absolutely needed to develop standard protocols for bedside use.
Severe Coronavirus infections could result in the patient getting an acute respiratory Tract Infection requiring the use of a Ventilator to sustain life. Vitamin D could be an adjunctive treatment protocol to help patients with Coronavirus.
Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS)
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
Low Vitamin D Status Occurs in 90% of Patients with ARDS and Is Associated with Longer Duration of Mechanical Ventilation
Please discuss the above with your Medical Doctor to see if the information may be of help. Self Medicating without the advice of your Medical Doctor(s) is not recommended.
The Truth About Cell Phone Radiation and 5G by Theodora Scarato.
Video is courtesy of the The Real Truth About Health YouTube channel
New York, NY, July 22, 2019. The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation 4G and 5G telecommunication technologies to plants, animals and humans.
There is particular urgency at this time as new antennas will be densely located throughout residential neighborhoods using much higher frequencies, with greater biologically disruptive pulsations, more dangerous signaling characteristics, plus transmitting equipment on, and inside, homes and buildings. The Advisors to The Appeal recommend UNEP seriously weigh heavily the findings of the independent, non-industry associated EMF science
Click on this link to view: The National Toxicology Program (NTP) concluded in two final reports released November 1, 2018, that there is clear evidence that male rats exposed to high levels of radio frequency radiation (RFR), like that used in 2G and 3G cell phones, developed cancerous heart tumors. There was also some evidence of tumors in the brain and adrenal gland of exposed male rats.
Posted by Vincent Banial
What are the health effects of mobile phones and wireless radiation?
The truth about mobile phone and wireless radiation by Dr. Devra Davis.
In this Dean’s Lecture, epidemiologist and electromagnetic radiation expert, Dr. Devra Davis, will outline the evolution of the mobile phone and smartphone, and provide a background to the current 19 year old radiation safety standards (SAR), policy developments and international legislation. New global studies on the health consequences of mobile/wireless radiation will be presented, including children’s exposure and risks.
Video is courtesy of the The University of Melbourne YouTube channel
There is also a great Time Magazine article which discussed Dr. Devra Davis’s research into Wireless radiation. Click on this link to visit the Time.com website to read their posted article titled: “Health: A Cancer Muckraker Takes on Cell Phones“.
Posted by Vincent Banial
You no longer need to grow a Marijuana plant to extract THC and CBD. You can get both by using Brewer’s Yeast and Sugar. You also get purer products. For example you can make CBD without the worry of it also containing THC.
This is revolutionary. It could eliminate huge Marijuana plant grow operations. It could also produce Cannabinoids which cannot be obtained from Marijuana plants. The consistency and purity of the produced product can be regulated to be uniform from batch to batch. This new process offers great potential in finding, via Medical Research Studies, new medical benefits of THC, CBD and other Cannabinoids.
Cristina Sánchez has been studying Cannabis for fifteen years at Complutense University in Madrid Spain. She has discovered that THC from Cannabis can kill Cancer cells.
Being able to produce Medical Cannabis products like THC in a pure form using Brewer’s Yeast opens up a lot of potential in the Medical field as you can maintain purity and quality in each batch produced. For example, there have been documented cases of patients who have seizures and are helped by CBD. You also eliminate the potential use of Pesticides in Plant Grow Operations.
Click on this link to visit the ScienceDaily website to read the newly published research from the University of California – Berkeley: “Yeast produce low-cost, high-quality cannabinoids.” ScienceDaily. ScienceDaily, 27 February 2019. <www.sciencedaily.com/releases/2019/02/190227131838.htm>.
Click on this link to visit the website of the journal Nature and read the abstract of the February 27 2019 published research article titled: “Complete biosynthesis of cannabinoids and their unnatural analogues in yeast“.
Click on this link to visit the ScienceDaily website to read the research report titled: “Benefits of medical marijuana for treatment of epilepsy examined“
Click on this link to visit the Bloomberg website to read their page about Demetrix Inc.
The information provided about cannabis is for informational purposes only. Please consult your physician before making any medical decisions.
Posted by Vincent Banial
Having Bad Breath could be a Major Risk Factor in developing Alzheimer’s Disease and Cardiovascular Disease.
A new Medical Study just released sheds light on P. gingivalis colonization in a human Brain as being the cause of developing Alzheimer’s Disease. The study also found that 100% of patients with Cardiovascular Disease had P. gingivalis arterial colonization.
The medical study is published by American Association for the Advancement of Science – Science Advances. Click on this link to visit the Science Advances site to read the study titled “Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors“.
The following are brief excerpts (you can read the full Study at the link noted above) from this new Research Study:
“The bacterium called gingipains (P. gingivalis) were identified in the brain of Alzheimer’s patients.”
Video is courtesy of OSH News Network YouTube Channel
“Oral P. gingivalis infection in mice resulted in brain colonization and increased production of Aβ1–42, a component of amyloid plaques. Further, gingipains were neurotoxic in vivo and in vitro, exerting detrimental effects on tau, a protein needed for normal neuronal function.”
“Alzheimer’s disease (AD) patients exhibit neuroinflammation consistent with infection, including microglial activation, inflammasome activation, complement activation, and altered cytokine profiles (1, 2). Infectious agents have been found in the brain and postulated to be involved with AD, but robust evidence of causation has not been established (3).”
“In Apoe−/− mice, oral infection with P. gingivalis, but not with two other oral bacteria, results in brain infection and activation of the complement pathway (14). In transgenic mice overexpressing mutated human amyloid precursor protein (hAPP-J20), oral infection with P. gingivalis impairs cognitive function, increases the deposition of AD-like plaques, and results in alveolar bone loss compared to control hAPP-J20 mice (15). P. gingivalis lipopolysaccharide has been detected in human AD brains (16), promoting the hypothesis that P. gingivalis infection of the brain plays a role in AD pathogenesis (17).”
“P. gingivalis is mainly found during gingival and periodontal infections; however, it can also be found at low levels in 25% of healthy individuals with no oral disease (18). Transient bacteremia of P. gingivalis can occur during common activities such as brushing, flossing, and chewing, as well as during dental procedures (19), resulting in documented translocation to a variety of tissues including coronary arteries (20), placenta (21), and liver (22).”
“A recent study found that 100% of patients with cardiovascular disease had P. gingivalis arterial colonization.” (23).
Video is courtesy of John Douillard YouTube Channel
Click on this link to visit the New Scientist website to reqd their article titled “We may finally know what causes Alzheimer’s – and how to stop it“.
Posted by: Vincent Banial
Really insightful article about about who owns academic research online.
Over half of all research, according to one study, is now published by the big five of academic publishing. To view research papers one has to go thru a paywall and pay for access to each research paper.
Most academic research is funded by Governmental Agencies. So the Taxed payers pay for the research to be done. Ask yourself this question: Since Tax Payer money funded the Academic Research, then should all resulting research papers be available to read for free?”
Video is courtesy of the Life Extension Advocacy Foundation YouTube Channel
Unfortunately at present if you want to view the results and read the published research papers one has to pay the private publishers via website Paywalls to access the research papers.
A new alternative has appeared, that being Open Access: “free availability on the public internet,” Click on this line to visit PLOS ONE – an Open Access site
This really good article is about Alexandra Elbakyan, a gifted programmer, who setup Sci-Hub – a site where one can download research papers for free.
The major publishers of Academic Research papers make a fortune and see Open Access and Alexandra’s Sci-Hub as cutting into their profits and ability to Hoard ever More Money by raising prices. So they have sued Alexandra Elbakyan. The lawsuits have impacted Internet Service providers and some believe hinder a free and open Internet.
Click on this line to the visit The Verge website to read their article titled:
Back in 2007, the American Association for Cancer Research published Information about research which was presented at their annual meeting by
BIDMC, Harvard University, Boston, MA
The closing important paragraph from the Abstract published by the Cancer Research Journal is below:
Cumulatively, these studies indicate that THC has anti-tumorigenic and anti-metastatic effects against lung cancer. Novel therapies against EGFR overexpressing, aggressive and chemotherapy resistant lung cancers may include targeting the cannabinoids receptors.
Posted by: Vincent Banial
Harvard University brought together researchers studying Marijuana’s health impacts with policymakers who are working to implement new laws in ways that will benefit and protect public health.
Video courtesy of the Harvard University YouTube channel
Click on this link to visit the National Cancer Institute website.
The following is from the National Cancer Institute webpage linked to above titled “Cannabis and Cannabinoids (PDQ®)–Patient Version
Questions and Answers About Cannabis”
Have any preclinical (laboratory or animal) studies been conducted using Cannabis or cannabinoids?
Preclinical studies of cannabinoids have investigated the following:
Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells.
A laboratory study of cannabidiol (CBD) in estrogen receptor positive and estrogen receptor negative breast cancer cells showed that it caused cancer cell death while having little effect on normal breast cells. Studies in mouse models of metastatic breast cancer showed that cannabinoids may lessen the growth, number, and spread of tumors.
A review of 34 studies of cannabinoids in glioma tumor models found that all but one study showed that cannabinoids can kill cancer cells without harming normal cells.
A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC may make chemotherapy such as temozolomide more effective.
Posted by: Vincent Banial
Professor Matthew Walker PhD, Director of UC Berkeley’s Sleep and Neuroimaging Lab discusses the latest discoveries about sleep and how it impacts our life, wellness, and lifespan.
Video is courtesy of the Talks at Google YouTube channel.
A new study has been published Mar 06 2018, in the Peer-Reviewed Medical Journal called Journal of the American Medical Association (or JAMA). The Study found that PSA test screening did not achieve its aim of diagnosing fast-growing cancers in time to treat them and prevent Deaths.
Video is courtesy of the University of Bristol YouTube Channel
Title: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial
Author: Martin, Richard M.; Donovan, Jenny L.
Publisher: American Medical Association
Date: Mar 6, 2018
There were men who were tested and the PSA Test found that they had a High PSA. Of those who agreed to further treatment during the study, some men were seriously harmed by treatment. There were 8 deaths in the screening group related to either the biopsy or prostate cancer treatment and 7 in the control group.
Click on this Link to the study published In JAMA on on Mar 06 2018 and titled “Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer MortalityThe CAP Randomized Clinical Trial“.
Posted by Vincent Banial
Chemotherapy can be an effective treatment for Hodgkin’s disease (HD) – a type of lymphoma, which is a blood cancer. Chemotherapy can also be an effective form of treatment for Testicular Cancer.
What about other Cancers?
The following is taken from the abstract of that research Study :
“The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.”
The conclusion as found in the abstract was:
“it is clear that cytotoxic chemotherapy only makes a minor contribution to cancer survival. To justify the continued funding and availability of drugs used in cytotoxic chemotherapy, a rigorous evaluation of the cost-effectiveness and impact on quality of life is urgently required.”.
Found a link using a web search. The link is below ( you have to copy and paste the URL if you wish to visit their site – as you would from a web search):
Basically that is supposed to be a PDF of the results from that study published on Dec 2004 in Clinical Oncology. It lists over twenty different Cancers and the percentage increases in 5 year survival rates for those patients who received Chemotherapy treatment for said Cancer.
Clinical Oncology had also published another research study in November 2004. You can view an abstract at nature.com by clicking on this line.
The following was the conclusion of the Nov 2004 published in Nov 2004:
“Adjuvant chemotherapy after potentially curative surgery can improve 5-year survival by 4% in patients with early-stage non-small-cell lung cancer (NSCLC, stages IB–IIIA).”.
So after surgery, Chemotherapy may increase the 5 year survival rate in about 4% of the patients. Yes, only 4%.
Using the above quoted studies and being overly generous, in my opinion it may seem that Chemotherapy does not increase the 5 year Survival Rate for about 85% of patients with many forms of Cancer. The exception is that yes it may be a form of effective treatment for Hodgkin’s Disease and for the treatment of Testicular Cancer.
With some Cancers the study chart (see the link to the PDF above) shows Chemotherapy to have zero effect on 5 years Survival Rate.
That leaves the question: Why is Chemotherapy being given to Cancer patients?
Disclaimer: The above is posted for information purposes only. I am not giving Medical Advice. If you have a medical issue please consult with your Licensed Medical Doctor, Specialist or other Medical Professional.
Something which has apparently been known in Cancer Research circles, has been formally announced to the public.
“Cannabis has been shown to kill cancer cells in the laboratory” posted by the National Cancer Institue at cancer.gov
Photo courtesy of the United States Fish and Wildlife Service
The info below is from the website of the National Cancer Institute (https://www.cancer.gov)
Cannabis and Cannabinoids (PDQ®)–Patient Version
- Questions and Answers About Cannabis
- Current Clinical Trials
- About This PDQ Summary
- General CAM Information
- Evaluation of CAM Therapies
- Questions to Ask Your Health Care Provider About CAM
- To Learn More About CAM
- View All Sections
- Cannabis , also known as marijuana, is a plant grown in many parts of the world which produces a resin containing compounds called cannabinoids. Some cannabinoids are psychoactive (acting on the brain and changing mood or consciousness) (see Question 1).
- The use of Cannabis for medicinal purposes dates back to ancient times (see Question 3).
- By federal law, the possession of Cannabis is illegal in the United States outside of approved research settings. However, a growing number of states, territories, and the District of Columbia have enacted laws to legalize medical marijuana (see Question 1).
- In the United States, Cannabis is a controlled substance requiring special licensing for its use (see Question 1 and Question 3).
- Cannabinoids are active chemicals in Cannabis that cause drug -like effects throughout the body, including the central nervous system and the immune system (see Question 2).
- The main active cannabinoid in Cannabis is delta-9-THC. Another active cannabinoid is cannabidiol (CBD), which may relieve pain, lower inflammation, and decrease anxiety without causing the “high” of delta-9-THC (see Question 2).
- Cannabinoids can be taken by mouth, inhaled, or sprayed under the tongue (see Question 5).
- Cannabis and cannabinoids have been studied in the laboratory and the clinic for relief of pain, nausea and vomiting, anxiety, and loss of appetite (see Question 6 and Question 7).
- Cannabis and cannabinoids may have benefits in treating the symptoms of cancer or the side effects of cancer therapies. There is growing interest in treating children for symptoms such as nausea with Cannabis and cannabinoids, although studies are limited (see Question 7).
- Two cannabinoids (dronabinol and nabilone) are drugs approved by the U.S. Food and Drug Administration (FDA) for the prevention or treatment of chemotherapy -related nausea and vomiting (see Question 7 and Question 10).
- Cannabis has been shown to kill cancer cells in the laboratory (see Question 6).
- At this time, there is not enough evidence to recommend that patients inhale or ingest Cannabis as a treatment for cancer-related symptoms or side effects of cancer therapy (see Question 7).
- Cannabis is not approved by the FDA for use as a cancer treatment (see Question 9).
******* end of post from cancer.gov *******
The following are additional links with info related to Cannabis and THC being able to kill Cancer Cells:
Antineoplastic Activity of Cannabinoids
Cannabinoid Receptor Ligands Mediate Growth Inhibition & Cell Death In Mantle Cell Lymphoma
Δ9-Tetrahydrocannabinol Induces Apoptosis in Human Prostate PC-3 Cells via a Receptor-Independent Mechanism
Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma
Cannabinoid Receptors As Novel Targets for the Treatment of Melanoma
Photo of Cannabis plants courtesy of A7nubis and commons.wikimedia.org
Note from Vince: This is am extremely important change as the Cannabis grown by NIDA is an uncommon variety and apparently low in THC. The FDA could approve a Medical Study of the use of high THC Cannabis in the treatment of Cancer, but NIDA always had the final word. If they approved a medical study (their usual common response was “No”) the study had to use the NIDA supplied Cannabis variety.
WASHINGTON, D.C. — Today, the Drug Enforcement Administration (DEA) announced their intention to grant licenses to additional marijuana growers for research, thereby ending the DEA-imposed 48-year monopoly on federally legal marijuana. Since 1968, the University of Mississippi, under contract to the National Institute on Drug Abuse (NIDA), has maintained the only facility in the United States with federal permission to grow marijuana for research.
“It’s a complete and total end of the NIDA monopoly! There has been no production monopoly on any other Schedule I substance, like MDMA or LSD—only the cannabis plant. Licensing non-government cannabis producers, and thereby creating a path to FDA approval, will finally facilitate the removal of marijuana from Schedule I, and ultimately allow patients to receive insurance coverage for medical marijuana,” said Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).
MAPS has been working to eliminate this cannabis research blockade since 1999. NIDA’s marijuana is eligible for research, but cannot be sold as a prescription medicine, making it unacceptable to the Food and Drug Administration (FDA) for use in future Phase 3 studies. Ending the monopoly finally allows for a pathway to FDA approval for marijuana, which would thereby trigger rescheduling.
In 2001, MAPS partnered with University of Massachusetts-Amherst Professor Lyle Craker, Ph.D., to apply for a DEA license and end the monopoly. In 2007, after years of bureaucratic delays and lengthy legal hearings, a DEA Administrative Law Judge (ALJ) recommended that it would be in the public’s interest to grant Craker the license. In 2009, after almost two more years of delays and less than a week before the inauguration of President Obama, former DEA Administrator Michelle Leonhart rejected the ALJ recommendation. In 2011, Craker sued the DEA in the U.S. First Circuit Court of Appeals. In its 2013 decision, the Court uncritically accepted the DEA’s arguments that NIDA’s monopoly provided “an adequate supply produced under adequately competitive conditions.”
Since the 2013 decision, Craker’s argument that NIDA does not have an adequate supply has become significantly more apparent. NIDA has been unable to provide the strains requested for MAPS’ long-delayed Phase 2 clinical trial of smoked marijuana to treat symptoms of posttraumatic stress disorder (PTSD) in 76 U.S. veterans. As a result, the study is proceeding with lower potency marijuana than what MAPS researchers requested.
The DEA has previously claimed that U.S. international treaty obligations under the United Nations Single Convention on Narcotic Drugs (Single Convention) require a federal monopoly, but in April 2016, the State Department released a statement clarifying that the Single Convention does not in fact limit the number of U.S. marijuana producers.
Furthermore, the DEA’s 2009 rejection of the ALJ recommendation to license Craker relied heavily on a U.S. Department of Health and Human Services (HHS) protocol review process, which was eliminated in 2015.
MAPS’ upcoming Phase 2 clinical trial of marijuana for PTSD in veterans is in collaboration with investigators in Phoenix, Arizona, and at Johns Hopkins University, the University of Colorado, and the University of Pennsylvania. The study is funded by a $2.15 million grant to MAPS from the State of Colorado. The study has received full regulatory approval, and will be the first randomized controlled trial of whole plant marijuana as a treatment for PTSD.
Founded in 1986, MAPS is a non-profit research and educational organization working to evaluate the safety and efficacy of botanical marijuana as a potential prescription medicine for specific medical uses approved by the FDA.
- Official Statement from DEA
- 2007 DEA Administrative Law Judge Findings
- 2013 First Circuit Court Decision
- 2015 HHS Statement Ending PHS Protocol Review
- Legal analysis to be submitted in support of Craker’s new application
Additional information can be found at maps.org/research/mmj/dea-license.
Rick Doblin, Ph.D., MAPS Executive Director
Natalie Ginsberg, MAPS Policy & Advocacy Manager
Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
This TEDx Talk is titled “Making Peace with Cannabis“. It features Zach Walsh, PhD, who is an Assistant Professor in the UBC Department of Psychology and Co-Director for the Centre for the Advancement of Psychological Science and Law. He is also involved in a current study at UBC which is investigating treating PTSD using Medical Cannabis.
Video is courtesy of the TEDx Talks YouTube channel
Dr. Dominic D’Agostino is an Assistant Professor at the University of South Florida College Of Medicine, Molecular Pharmacology & Physiology where he develops and tests Metabolic Therapies, including alternative energy substrates and ketogenic agents for neurological disorders, Cancer and wound healing.
While studying the effects of gasses on the brains of Navy Seal divers, he developed an approach for metabolically starving Cancer Cells through diet and compressed oxygen, replacing chemotherapy, surgery, or radiation.
Video is courtesy of the TEDx Talks YouTube channel
Click on this link to visit the official US Government PubMed site to view research findings published by Dr. Dominic D’Agostino titled “Press-pulse: a novel therapeutic strategy for the metabolic management of cancer.”
Click on this link to visit the official site of Dr. Dominic D’Agostino.
Posted by Vincent Banial